o presente trabalho teve por objetivo verificar a possível associação entre alimentação no primeiro ano de vida e anemia ferropriva. Estudou-se uma amostra de 317 crianças com até 12 meses de idade, matriculadas e freqüentando quatro Centros de Saúde Escola do município de São Paulo. As informações sobre a alimentação foram obtidas pelo método de inquérito recordatório, em entrevista com as mães das crianças, na ocasião da consulta ou da vacinação. A presença de anemia foi verificada pela concentração de hemoglobina, determinada pelo método da cianometahemoglobina. Utilizou-se o critério recomendado pela Organização Mundial de Saúde (OMS) para diagnóstico da anemia, verificando-se a prevalência de 14,5 por cento entre toda a população e 22,4 por cento entre as crianças maiores de 180 dias. As associações entre anemia e duração do aleitamento materno exclusivo, idade de introdução de alimentos não lácteos e freqüência de consumo de alimentos fontes de ferro e/ou potenciadores da sua absorção não foram significantes. A ausência do aleitamento materno, até pelo menos 4 meses, associou-se à anemia. Nessa faixa etária encontraram-se 26,9 por cento de anêmicas entre as crianças que tomavam outros leites e 8,6 por cento entre as que só recebiam leite materno. A anemia não se associou às variáveis sócioeconômicas estudadas: escolaridade do pai, da mãe e renda familiar. / This study was made to find out the possible association between the diet in the first year of life and iron deficiency anemia. A sample of 317 infants aged 0-12 months was studied in four school health centers in the city of São Paulo. The informations about diet were obtained by the recordatory survey method, in interviews with the infant\'s mothers. The presence of anemia was verified by hemoglobin concentration, using the cianometahemoglobin method. The criteria recommended by the World Health Organization (WHO) was utilized for the diagnostic of anemia. The prevalence of 14,5 per cent was found in all the population and 22,4 per cent in infants aged more than 180 days. The associations between anemia and time of exclusively breast-feeding, and age of introduction of other foods and/or eating foods which enhance iron absorption were not significants. The absence of breast-feeding, until at least 4 months, were associated with anemia. In this age were found 26,9 per cent of anemics among infants receiving others milks and 8,6 per cent among those receiving only breast milk. Anemia was not associated with socioeconomic variables: parents education levels and familiar income.

Iron deficiency anemia (IDA) is the most common extraintestinal complication encountered in patients with Inflammatory Bowel Disease (IBD), and it is more prevalent in pediatric patients compared to adults (Rogler and Vavricka). The inflammation and blood loss from the disease impacts both the absorption and storage of iron in the body (Rogler and Vavricka). With the intent of establishing a standard of care for IDA treatment in patients with IBD, we conducted a prospective study of 104 consecutive pediatric patients to assess the safety and efficacy of intravenous (IV) iron therapy compared to oral therapy and no treatment, as well as the effects of iron therapy on patient quality of life. Efficacy was assessed by comparing the change in hemoglobin levels in the interval between admission to outpatient follow-up. The average time to the first ambulatory follow-up was 29.08 days. 69 patients received IV iron therapy, 17 patients received oral iron supplementation, and 18 patients had no treatment. Treatment with IV iron resulted in a statistically significant increase in hemoglobin levels (2.00 g/dL ± 1.57 g/dL, as mean ± standard deviation) from admission to the first follow-up ambulatory appointment (p < .0001). Patients receiving IV iron therapy also experienced a significantly greater mean increase in hemoglobin levels than those treated with oral iron (p = .0084) or no treatment (p = .0018). Further, patients treated with IV iron experienced a significant increase in their quality of life at follow-up compared to admission as measured by the Impact-III questionnaire (p = .0179). Our study illustrates the importance of screening pediatric patients with IBD for IDA and suggests that IV iron treatment is safe and more effective in raising hematologic and iron measures than orally- administered alternative options.

Anemia is a significant public health issue that affects a great number of people in developed and developing countries. The World Health Organization states when the Hb value is/dL in an adult male and/dL in a nonpregnant female, the individual is considered as anemic. Iron deficiency is one of the most common causes of anemia. Inadequate intake of iron, chronic blood loss, and/or a combination of both factors typically lead to iron deficiency anemia. In developed countries, chronic blood loss from gastrointestinal, genitourinary, and gynecological sources are the most common etiologies of iron deficiency anemia. Although there are reports of iron deficiency anemia leading to self-inflicted skin excoriation, there are few cases of chronic blood loss from skin excoriation resulting in severe iron deficiency anemia. We present a 49 year old female with significant past medical history of depression, anxiety and chronic back pain who presented after she was found to have profound anemia with hemoglobin of 4.1g/dl. During interviewing, she denied hematuria, hemoptysis, hematochezia, and had been without menstrual cycles for the past year. Urinalysis was negative for blood as well as two documented negative fecal occult blood tests. Iron studies completed showed severely reduced iron levels. Upon further interviewing, the patient reported a supposedly self-diagnosed keratin disorder. For the past ten years she has been self-treating the keratin disorder by applying topical tretinoin and then wrapping it in saran wrap. She would then peel off areas of skin over multiple areas of her body including all extremities and her face. Multiple pictures of bloody piles of tissue were shown. The patient required 3 units of packed red blood cells and was started on iron supplementation. Gastroenterology was consulted and agreed there was no GI source of her blood loss. Psychiatry further evaluated the patient and diagnosed her with obsessive-compulsive disorder with somatic delusions. The prevalence of anemia among chronic psychiatric patients is more frequent than general population. This coexistence deteriorates the quality of life of the patients, prolongs the psychiatric treatment period, and could even cause an increase in morbidity and mortality. Treatment-related factors, drugs taken, physical conditions, negative lifestyle habits, and nutritional disorders are the reasons for anemia among chronic psychiatric patients. Even though iron deficiency anemia in developed country is most often caused by chronic blood loss from gastrointestinal, genitourinary, and gynecological causes, it is important to evaluate for other factors when none of these are present. Psychiatric causes when warranted from history including somatic delusions from obsessive-compulsive disorder should be considered on the differential when other etiologies are less clear.

Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder characterized by a mutation of the neurofibromin 1 (NF1) gene, resulting in increased susceptibility for multiple tumors, namely, gastrointestinal stromal tumors (GISTs)-the most common types of mesenchymal neoplasms in the gastrointestinal tract. Despite these tumors' predilection for the stomach, it seems to be the least likely part of the gastrointestinal (GI) tract to be affected in cases of neurofibromatosis. Herein, we report a case of a 61-year-old male patient with known neurofibromatosis, who presented with acute blood loss anemia due to a recurrent gastric GIST, requiring partial gastrectomy due to its size and multiple recurrences.

No description available.

We estimated the prevalence of iron deficiency anemia (IDA) in women 1-year postpartum in central Montreal. Blood samples were obtained by venipuncture and questionnaires administered. Iron intake was assessed by a food frequency questionnaire. Mothers with at least two of the following laboratory values were considered to have IDA: serum ferritin (SF) < 12 mug/L, mean corpuscular volume (MCV) < 80 fL and hemoglobin (Hb) < 120 g/L. Blood samples were analysed for 201 women. The estimates of prevalence of anemia (Hb < 120 g/L), iron deficiency (SF < 12 mug/L) and IDA were 7.0% (95% confidence interval [CI] 3.8%-10.9%), 5.5% (95% CI 2.5%-8.9%) and 2.5% (95% CI 0.3%-4.7%) respectively. No significant differences were observed between level of income and anemia, iron deficiency and IDA rates. Anemia was not related to dietary iron intake. In conclusion, the prevalence of IDA is low among healthy women 1-year postpartum in central Montreal.

No description available.

Bibliography: leaves 148-163.

Bibliography: leaves 148-163. / xix, 163, [43] leaves : ill. ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Thesis (Ph.D.)--University of Adelaide, Dept. of Public Health, 2001

Iron deficiency anemia (IDA) is a common extra-intestinal manifestation of inflammatory bowel disease (IBD). It is particularly common in the pediatric population, with 40-60% of pediatric patients with IBD meeting criteria for anemia (Aljomah et al, 2018). A number of studies have examined the use of both IV and oral iron treatments to treat anemia in IBD, but few have examined the safety and efficacy of these treatments in children and how they impact a patient’s health-related quality of life. We conducted a prospective cohort study of 79 pediatric patients admitted to Boston Children’s Hospital for management of their IBD. 48 of these patients received IV iron, 13 received oral iron, and 12 were not treated with either. Treatment with IV iron resulted in a statistically significant increase in hemoglobin of 1.75g/dL+/-1.4g/dL (mean +/- SD) from admission to the time of their first post-discharge visit (p=0.0001). Prescription of oral iron at the time of discharge did not result in a significant increase in hemoglobin over the same interval (p=0.481). Though there was a positive trend, IV iron treatment did not result in a significant change in health-related quality of life (HRQOL) measurements as measured by the IMPACT-III questionnaire (p=0.06). Our study suggests that IDA is common in patients admitted for management of their IBD, IV iron is more efficacious in raising hemoglobin, and that larger studies will be needed to more fully demonstrate the impact of effective iron repletion on overall quality of life in these patients.